Exploring the characteristics of suboptimally controlled patients after 24weeks of basal insulin treatment: An individualized approach to intensification - PubMed (original) (raw)
Exploring the characteristics of suboptimally controlled patients after 24weeks of basal insulin treatment: An individualized approach to intensification
Kamlesh Khunti et al. Diabetes Res Clin Pract. 2017 Jan.
Free article
Abstract
Aim: To identify characteristics of suboptimally controlled patients with type 2 diabetes (T2DM) on basal insulin treatment who may benefit from intensive titration or further intensification of treatment.
Methods: A post hoc analysis of SOLVE: a 24-week, international, observational study conducted in 17,374 patients with T2DM inadequately controlled on oral antidiabetic drugs (OADs) started on once-daily insulin detemir. Patients were divided into two groups based on whether they achieved HbA1c<7.0% (<53.0mmol/mol) or not at final visit.
Results: Suboptimal glycemic control (HbA1c⩾7.0 [⩾53.0mmol/mol]) was independently associated with several baseline characteristics including higher baseline HbA1c (odds ratio [95% confidence interval]: 1.56 [1.50;1.62]; p<0.0001) and body mass index (BMI) (1.03 [1.02;1.04]; p<0.0001), longer duration of diabetes (5-10years: 1.44 [1.25;1.66]; >10years: 1.44 [1.17;1.77]; p<0.0001), and greater number of OADs (two OADs: 1.27 [1.12;1.44]; >2 OADs: 1.38 [1.14;1.66]; p=0.0003). Overall reporting of hypoglycemia was low; fewer patients with HbA1c⩾7.0% (⩾53.0mmol/mol) reported hypoglycemic events compared with patients with HbA1c<7.0% (9.8% vs. 12.5%, respectively; p<0.001).
Conclusions: Baseline characteristics related to severity of disease were strongly associated with suboptimal glycemic control in patients with T2DM receiving basal insulin. These factors may help clinicians in identifying patients who may require an individualized approach to titration or intensification of treatment.
Trial registration: NCT00740519.
Keywords: Basal insulin detemir; HbA1c; Hypoglycemia; Type 2 diabetes mellitus.
Copyright © 2016 The Author(s). Published by Elsevier B.V. All rights reserved.
Similar articles
- Weight-neutral effect of once-daily insulin detemir in Chinese type 2 diabetes patients: subgroup analysis of the SOLVE study.
Pan C, Han P, Ji L, Ji Q, Lu J, Lin J, Liu J, Su B, Shi J, Wang P. Pan C, et al. J Diabetes. 2015 Mar;7(2):222-30. doi: 10.1111/1753-0407.12179. Epub 2014 Sep 4. J Diabetes. 2015. PMID: 24909984 - Clinical Inertia in the Management of Type 2 Diabetes Mellitus: A Systematic Review.
Almigbal TH, Alzarah SA, Aljanoubi FA, Alhafez NA, Aldawsari MR, Alghadeer ZY, Alrasheed AA. Almigbal TH, et al. Medicina (Kaunas). 2023 Jan 16;59(1):182. doi: 10.3390/medicina59010182. Medicina (Kaunas). 2023. PMID: 36676805 Free PMC article. Review.
Cited by
- Sex differences in type 2 diabetes: an opportunity for personalized medicine.
Johnson ML, Preston JD, Rashid CS, Pearson KJ, Ham JN. Johnson ML, et al. Biol Sex Differ. 2023 Dec 13;14(1):88. doi: 10.1186/s13293-023-00571-2. Biol Sex Differ. 2023. PMID: 38093356 Free PMC article. - Baseline nocturnal glucose change: A predictor of the treatment effect of bolus intensification in insulin-treated type 2 diabetes.
Peters AL, Piletič M, Ejstrud J, Salvesen-Sykes K, Snyder J, Bowering K. Peters AL, et al. Diabetes Obes Metab. 2019 Jul;21(7):1752-1756. doi: 10.1111/dom.13729. Epub 2019 Apr 23. Diabetes Obes Metab. 2019. PMID: 30924578 Free PMC article. Clinical Trial. - Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis.
Bowering K, Rodbard HW, Russell-Jones D, Bode B, Harris S, Piletic M, Heller S, Woo V, Babu V, Dethlefsen C, Mathieu C. Bowering K, et al. Diabetes Ther. 2019 Feb;10(1):177-188. doi: 10.1007/s13300-018-0553-7. Epub 2018 Dec 13. Diabetes Ther. 2019. PMID: 30547388 Free PMC article. - Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0.
Owens DR, Landgraf W, Frier BM, Zhang M, Home PD, Meneghini L, Bolli GB. Owens DR, et al. Diabetes Obes Metab. 2019 Feb;21(2):321-329. doi: 10.1111/dom.13607. Diabetes Obes Metab. 2019. PMID: 30520217 Free PMC article. - Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Davies MJ, et al. Diabetes Care. 2018 Dec;41(12):2669-2701. doi: 10.2337/dci18-0033. Epub 2018 Oct 4. Diabetes Care. 2018. PMID: 30291106 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous